This business information is not released now.


Back
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.


J-Pharma Co., Ltd.
【Field/Business】
Pharmaceutical/Drug Discovery


last update:2013/4/24
Profile

Delegates :
Hitoshi Endou M.D., Ph.D.


Incorporated :
December  26 , 2005

Paid in Capital :
101 Million yen  

Employees :
5 人

Address :
1-513 Leading Venture Plaza, 75-1 Onocho, Tsurumi-Ku, Yokohama KANAGAWA
〒2300046

TEL/FAX :
45-506-1155 / 45-506-1155

URL:
http://www.j-pharma.com

Attachment :

Mission/Background :
J-Pharma Co. Ltd., was founded in 2005 by Dr. Hitoshi Endou, the former professor of Kyorin University, is a Japanese biopharmaceutical company with significant expertise in transporter target drug research and development. It enriches its product pipeline by Dr. Endou's original research compounds, through new molecular entity research in collaboration with universities both in Japan and USA.

Technology & Business
LAT1 has been patented by J-Pharma. J-Pharma has developed a variety ofLAT1-specific inhibitors which inhibit essential amino acids (i.e. like leucine, isoleucine, methionine, phenylalanine and valine) uptake into cancer cells. LAT1 selective inhibition stimulates cancer cells apoptosis via the so called 'starve-out' strategy, a specific LAT1-mediated cell signaling pathway. LAT1 is an Onco-fetal membrane protein highly expressed in transformed cancer cells. LAT1 is found in a few normal tissues like bone marrow, reproductive organs and brain. LAT2 is a homolog of LAT1and expressed ubiquitously in normal tissues, but not expressed in cancer cells.
Products & Service
Products & Service Name
Stage
Outline
Milestone
JPH203
Preclinical
Anti cancer drug
Clinical study in 2013
JPH211
Others
Immuno-histochemical staining diagnostic kits of cancer malignancy
NDA in 2013
JPH 257
Discovery
PET/CT compounds
Clinical research in 2013
JPH367
Preclinical
Anti-hyperuricemic agent
Clinical study in 2015




Highlights
JPH203: Clinical study approved by Kitasato university IRB in 2012.
JPH211: Licensed with Japanese diagnosis company for prostate cancer in 2013.
Hot news

Alliance strategy
Product for license-out; JPH 203 anti cancer drug, JPH 211 Immuno-histochemical staining
diagnostic kits, JPH 223 PET/CT compounds, JPH367 Anti-hyperuricemic agent.
Transporter intellectual property for license-out LAT1, LAT3, URAT1, OAT1,2,3,4, CT2


 
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.